Allakos (ALLK) Earnings Date & Reports

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases... Show more

Industry: #Pharmaceuticals Major

Get AI intraday signals

A.I. Advisor

published Earnings

ALLK is expected to report earnings to fall ∞% to -28 cents per share on May 07

Q1'25

Est.

$-0.29

Q4'24

Beat

by $0.19

Q3'24

Beat

by $0.04

Q2'24

Beat

by $0.03

Q1'24

Missed

by $0.37

The last earnings report on March 12 showed earnings per share of 0 cents, beating the estimate of -18 cents. With 10.91M shares outstanding, the current market capitalization sits at 19.57M.

View a ticker or compare two or three

Compare

ALLK